Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy. Here we design an ALVAC/Pentavalent B/E/E/E/E vaccine to increase the diversity of gp120 motifs in the immunogen to elicit a broader an...

Full description

Saved in:

Bibliographic Details
Published in:	Nature communications Vol. 8; no. 1; pp. 15711 - 15
Main Authors:	Bradley, Todd, Pollara, Justin, Santra, Sampa, Vandergrift, Nathan, Pittala, Srivamshi, Bailey-Kellogg, Chris, Shen, Xiaoying, Parks, Robert, Goodman, Derrick, Eaton, Amanda, Balachandran, Harikrishnan, Mach, Linh V., Saunders, Kevin O., Weiner, Joshua A., Scearce, Richard, Sutherland, Laura L., Phogat, Sanjay, Tartaglia, Jim, Reed, Steven G., Hu, Shiu-Lok, Theis, James F., Pinter, Abraham, Montefiori, David C., Kepler, Thomas B., Peachman, Kristina K., Rao, Mangala, Michael, Nelson L., Suscovich, Todd J., Alter, Galit, Ackerman, Margaret E., Moody, M. Anthony, Liao, Hua-Xin, Tomaras, Georgia, Ferrari, Guido, Korber, Bette T., Haynes, Barton F.
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 08.06.2017 Nature Publishing Group Nature Portfolio
Subjects:	45/77 631/250/255/1901 631/250/590 692/308/2778 82/1 82/47 82/80 Acquired immune deficiency syndrome AIDS Antibodies Health risks HIV Human immunodeficiency virus Humanities and Social Sciences Immunization Infections multidisciplinary Proteins Science Science (multidisciplinary) Vaccines Viruses Thailand United States > US Maryland Massachusetts New Jersey
ISSN:	2041-1723, 2041-1723
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!